Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, announced on Nov. 17 that the U.S. Food and Drug Administration (FDA) has approved LEMBAZTM (adrabetadex), the first medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C (NPC) and the first medicine to improve survival in infantile-onset NPC (I-NPC). LEMBAZ is approved for adults and children with NPC who had neurological manifestations that started before the age of 6. The company received a Priority Review Voucher upon this approval.
The efficacy of LEMBAZ was based on an overall survival analysis in people with I-NPC treated with LEMBAZ across three clinical studies and an Expanded Access Program, compared with matched external controls. The FDA determined that this comparison served as the adequate and well-controlled study supporting approval. The analysis showed a 55 percent reduction in the risk of mortality.
